Pacific Biosciences
PACB
PACB
225 hedge funds and large institutions have $475M invested in Pacific Biosciences in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 65 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
225
Holders Change
-1
Holders Change %
-0.44%
% of All Funds
2.99%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
38
Increased
75
Reduced
65
Closed
35
Calls
$6.83M
Puts
$4.17M
Net Calls
+$2.65M
Net Calls Change
+$2.97M
Top Buyers
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$37.4M |
| 2 |
Millennium Management
New York
|
+$12.2M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$8.96M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.83M |
| 5 |
Morgan Stanley
New York
|
+$3.22M |
Top Sellers
| 1 |
Capital World Investors
Los Angeles,
California
|
-$5.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.42M |
| 3 |
Jane Street
New York
|
-$4.11M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.79M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$3.09M |
